Fiera Capital Corp Has $83.39 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Fiera Capital Corp reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 130,521 shares of the company’s stock after selling 3,577 shares during the quarter. Fiera Capital Corp owned about 0.16% of IDEXX Laboratories worth $83,389,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $30,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories during the third quarter worth $31,000. Armstrong Advisory Group Inc. lifted its holdings in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after buying an additional 19 shares during the period. Salomon & Ludwin LLC bought a new stake in IDEXX Laboratories during the third quarter valued at $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in IDEXX Laboratories during the 3rd quarter worth about $35,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 18,180 shares of company stock valued at $11,626,996. Corporate insiders own 0.98% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of recent analyst reports. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. BTIG Research lowered their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $630.73 on Friday. The company has a market cap of $50.36 billion, a P/E ratio of 48.26, a PEG ratio of 3.86 and a beta of 1.67. The company has a fifty day simple moving average of $679.11 and a 200 day simple moving average of $669.15. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.